Purpose: Dieckol, a phlorotannin compound isolated from Ecklonia cava, has been reported to have antioxidant, antiviral, anti-inflammatory, and anticancer properties. The purpose of this study was to investigate its anticancer effects on human breast cancer cell lines. Methods: In this study, the viability of two human breast cancer cell lines SK-BR-3 and MCF-7 was investigated after dieckol treatment using a WST-1 assay. Apoptosis and cell cycle distribution were assayed via Annexin V-fluorescein isothiocyanate and propidium iodide staining followed by flow cytometric analysis. Immunoblotting analysis was also performed using Bax/Bcl-2 to determine whether the dieckol-induced apoptosis was mediated by the intrinsic apoptotic pathway. Results: In a dose dependent manner, dieckol reduced the number of viable cells and increased the number of apoptotic cells. The effect of dieckol on the cell cycle distribution was analyzed using flow cytometry. Dieckol treatment significantly increased the percentage of MCF-7 and SK-BR-3 in the G2/M phase. Immunoblot analysis revealed that 24 hours of dieckol exposure increased the Bax/Bcl-2 ratio. Conclusion: Dieckol induced cytotoxicity in MCF-7 and SK-BR-3 human breast cancer cells inducing apoptosis and cell cycle arrest. Therefore, it is suggested that dieckol may be a potential therapeutic agent for breast cancer.
INTRODUCTION
With advances in treatment, earlier detection, and the increased awareness of health care, the mortality rate due to breast cancer has been decreasing over the last few decades [1] . However, breast cancer is still a major cause of morbidity and mortality among women worldwide. Moreover, it is the second most common cancer in Korean women [2] . Generally, the treatment of breast cancer consists of surgery, chemotherapy, radiation therapy, antihormonal therapy, and/or targeted therapy (trastuzumab). These treatment strategies vary for each patient, depending on the breast cancer subtype. Since breast cancer is a disease characterized by multiple subtypes, there are differences in disease prognosis and the response to diverse therapeutic options [3] [4] [5] . The recurrence of breast cancer can occur at any time, from months to years after the initial treatment. Late recurrence is not common in breast cancer but may arise at any stage [6] . Prognosis is poor in patients with recurrent or metastatic breast cancer, despite adequate treatments such as chemotherapy or radiation therapy. Additionally, cancer treatment is known to cause adverse effects including febrile neutropenia, hair loss, peripheral neuropathy, ototoxicity, and nephrotoxicity [7] [8] [9] . These events decrease the patient's compliance to treatment. Therefore, new therapeutic options are needed with consideration of the patient's compliance and quality of life.
Extensive research has revealed that numerous natural products, especially those obtained from aquatic plants, have potential chemopreventive and antineoplastic effects on breast cancer [10, 11] . Among these, brown algae, i.e., Ecklonia cava, are used as health foods in East Asia. In addition, they are used in the production of many food products [12, 13] . E. cava contains various natural components, such as carotenoids, fucoidans, and phlorotannins. Dieckol, a phlorotannin from E. cava has antioxidant, antithrombotic, profibrinolytic properties [14, 15] . Recent studies have reported that this phlorotannin has an inhibitory effect on cancer metabolism [16, 17] . However, the effect of dieckol on cancer cell growth has not been extensively studied in breast cancer.
Therefore, in this study, the effect of dieckol isolated from E. cava was evaluated on human breast cancer cell growth. Further, its mechanism of action on the cell lines, i.e., induction of apoptosis and/or cell cycle arrest was investigated. 
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Chemical treatment and cell viability assay
Assays of cell cycle
For the analysis of the cell cycle, the dieckol-treated cells were col- 
RESULTS
Dieckol suppresses breast cancer cell growth
The inhibitory effect of dieckol on MCF-7 and SK-BR-3 cell growth was investigated. These cells were exposed to various concentrations of dieckol for 24 hours, and the cell viability was assessed using a WST-1 assay. The results showed a dose-dependent effect on cell viability. Cell death reached 57.55% with 400 µg/mL of dieckol and 
Apoptosis induced by dieckol
To investigate the mechanism of the cell death induced by this Bax/Bcl-2 ratio in the breast cancer cell lines treated with dieckol
To determine the amount of dieckol-induced apoptosis through the modulation of the Bcl-2 proteins, the Bax/Bcl-2 ratios were measured at the protein level. These ratios in the MCF-7 and SK-BR-3 cells were determined at 24 and 48 hours after treatment with dieckol (100 µg/mL). The expression of β-actin (42 kDa) was used as a loading control. The Bax/Bcl-2 ratio was higher in the dieckol-treated group than in the control at 24 hours (p < 0.001) ( Figure 3A) . However, it was observed that in the MCF-7 cell line, this ratio was not significantly different between the control and the dieckol-treated group at 48 hours. 
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The ratios measured in SK-BR-3 cells are displayed in Figure 3B . There was a significant difference (p < 0.001) in the Bax/Bcl-2 ratio between the cells treated with dieckol for 24 and 48 hours.
Cell cycle arrested induced by dieckol
The effect of dieckol on the cell cycle distribution was analyzed using flow cytometry. As shown in Figure 4A , However, this finding warrants further investigation.
The cell cycle is a set of events responsible for cell replication [26] . In normal cells, the cell cycle is controlled by various signaling pathways that detect cellular events, such as cellular stress or DNA damage.
These pathways are generally referred to as cell cycle checkpoints.
These checkpoints play a role in correcting and repairing cellular damage, cell cycle arrest, and apoptosis [27, 28] . In tumor metabolism, uncontrolled cell proliferation is observed because of malfunctions in the regulatory processes. In addition, evading cell cycle arrest is the most frequently observed phenomenon. Checkpoints at the G1/S and G2/M transitions are crucial to cell cycle progression without accumulation of genetic abnormalities [29, 30] . In this study, the MCF-7
and SK-BR-3 cells treated with a concentration of 100 µg/mL of dieckol for 48 hours were arrested at the G2/M phase. These findings indicate that the dieckol-induced cell cycle arrest occurred regardless of the cell line. However, the precise mechanisms of the cell cycle arrest in the MCF-7 and SK-BR-3 cells are unknown. Therefore, further investigation is needed.
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In conclusion, this study indicated that dieckol suppresses cell proliferation, activates the intrinsic apoptotic pathway, and induces cell cycle arrest at the G2/M phase. Although further investigations are required to be conducted in vivo, these findings can support the development of dieckol as a potential agent for breast cancer treatment.
